Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trialResearch in context

Summary: Background: Previous trials have indicated the potential of arbaclofen for improving social difficulties among autistic children and adolescents with fluent speech. AIMS-2-TRIALS-Clinical Trial 1 (AIMS-2-CT1) examined whether arbaclofen is superior to placebo in improving social function a...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	M. Parellada, A. San José Cáceres, R. Delorme, A. Moscoso, C. Moreno, R. Calvo, R. Canal-Bedia, M.A. Franco Martín, T. Charman, A. Strydom, J.R. Parr, E. Urbiola Merino, M. Burdeus-Olavarrieta, P. Hernández Jusdado, A. Solis, M. Lucas, L. Sipos, P. González Navarro, A. Blázquez, L. Lázaro, A. Tomás, E. Humeau, S. Antoun, J. Cooke, M. Megalogeni, H. Liang, V.B. de-Vena-Díez, H. Leonard, N. White, P. Wang, K. Walton-Bowen, I. Winter-van Rossum, D. Murphy, C. Arango
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2026-02-01
Serier:	EClinicalMedicine
Fag:	Clinical trial RCT Arbaclofen Autism AIMS-2
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2589537026000076
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!